Zylox-Tonbridge Medical Technology (HKG:2190) reported a profit attributable to shareholders of 100.3 million yuan for 2024, rebounding from a loss of 78.7 million yuan in the previous year.
Earnings per share were 0.3057 yuan, according to a Thursday filing with the Hong Kong bourse.
Revenue for the year rose 48% to 782.5 million yuan from 527.8 million yuan in the prior year.